Current Report Filing (8-k)
August 14 2018 - 4:38PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of the Securities Exchange Act Of 1934
August 14, 2018
Date of Report (Date of earliest event reported)
ACURA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in
Charter)
State of New York
|
1-10113
|
11-0853640
|
(State of Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer
Identification Number)
|
616 N. North Court, Suite 120
Palatine, Illinois 60067
(Address of principal executive offices)
(Zip Code)
(847) 705-7709
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d- 2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company
¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 2.02
|
Results of Operations and Financial Condition
|
On August 14, 2018 we issued a press release
disclosing the financial results for our second quarter ended June 30, 2018. A copy of our press release is being furnished as
Exhibit 99.1 hereto.
|
Item 9.01
|
Financial Statements and Exhibits
|
|
Exhibit Number
|
Description
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
ACURA PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Peter A. Clemens
|
|
|
|
Peter A. Clemens
Senior Vice President & Chief Financial Officer
|
|
Date: August 14, 2018
Exhibit Index
|
Exhibit Number
|
Description
|
Acura Pharmaceuticals (CE) (USOTC:ACUR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acura Pharmaceuticals (CE) (USOTC:ACUR)
Historical Stock Chart
From Sep 2023 to Sep 2024